Overview
- 44 inspections across 43 sites are on record.
- 110 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-02-11.
At a glance
Inspections
44
Sites
43
Observations
110
Career since
Aug 2019
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Eli Lilly and Company | 11 Feb 2026 | Human Drugs | On file |
| Health Pharma USA LLC | 18 Nov 2025 | Human Drugs | On file |
| Nephron SC, LLC | 22 Aug 2025 | Human Drugs | On file |
| Hikma Injectables USA Inc. | 8 Aug 2025 | Human Drugs | On file |
| Little Moon Essentials LLC | 10 Jul 2025 | Human Drugs | On file |
Sites inspected
Eli Lilly and CompanyConcord, United States1 insp.
Health Pharma USA LLCRahway, United States1 insp.
Nephron SC, LLCWest Columbia, United States1 insp.
Hikma Injectables USA Inc.Dayton, United States1 insp.
Little Moon Essentials LLCDania Beach, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Suchan Kim2 shared
Yvins Dezan2 shared
Tonia F Bernard2 shared
Young K Chou1 shared
Jessica S Estriplet1 shared
Luxuly Abraham1 shared
Christian F Gomez Lugo1 shared
Stephenie M Ortiz1 shared
Charlotte P Chang1 shared
Kellia N Hicks1 shared
Full investigator report
Get the verbatim findings behind Rose L Jean-Mary's 110 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site